ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-895-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.82 million
Profitability
Miscellaneous
Employees296
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, August, 2nd. The biotechnology company reported ($0.29) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.03. The biotechnology company had revenue of $15.54 million for the quarter, compared to the consensus estimate of $10.33 million. ImmunoGen had a negative net margin of 357.97% and a negative return on equity of 573.13%. View ImmunoGen's Earnings History.
When is ImmunoGen's next earnings date?
What guidance has ImmunoGen issued on next quarter's earnings?
ImmunoGen updated its FY 2019 earnings guidance on Friday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $40-45 million, compared to the consensus revenue estimate of $36.12 million.
What price target have analysts set for IMGN?
10 brokers have issued 12 month price objectives for ImmunoGen's shares. Their predictions range from $2.50 to $5.00. On average, they anticipate ImmunoGen's share price to reach $3.28 in the next twelve months. This suggests a possible upside of 35.8% from the stock's current price. View Analyst Price Targets for ImmunoGen.
What is the consensus analysts' recommendation for ImmunoGen?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 sell rating, 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ImmunoGen.
What are Wall Street analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. According to Zacks Investment Research, "ImmunoGen reported dismal first-quarter results wherein earnings and sales missed expectations. The company is progressing with its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies, which not only validate its technology but also provide it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. In March, the company received a major setback as the candidate failed in its phase III monotherapy study. The ovarian cancer space is also highly competitive, which is also a matter of concern for the company. The company’s shares have underperformed the industry so far this year." (5/8/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $18 price target on shares of ImmunoGen is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF analysis is based on: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 12.0%, and tax rate of 12% beginning in FY 2028. Note, our $18 price target is leveraged on the outcome of the mirvetuximab soravtansine’s Phase 3 FORWARD I study, which represents approximately 89% of our target (risk-adjusted NPV of $16 per share). Key risks to our valuation include: emergence of ADC-related safety concerns, clinical, regulatory, and financials risks. ImmunoGen, Inc." (1/3/2019)
Has ImmunoGen been receiving favorable news coverage?
Media headlines about IMGN stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ImmunoGen earned a news impact score of -1.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for ImmunoGen.
Are investors shorting ImmunoGen?
ImmunoGen saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 6,840,000 shares, an increase of 41.0% from the August 30th total of 4,850,000 shares. Based on an average trading volume of 1,890,000 shares, the short-interest ratio is presently 3.6 days. Currently, 4.6% of the shares of the stock are sold short. View ImmunoGen's Current Options Chain.
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Eidos Therapeutics (EIDX), Opko Health (OPK), Radius Health (RDUS), BELLUS Health (BLUSF), Enanta Pharmaceuticals (ENTA), Turning Point Therapeutics (TPTX), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Zymeworks (ZYME) and Endo International (ENDP).
What other stocks do shareholders of ImmunoGen own?
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)
- Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)
- Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)
- Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)
- Mr. David G. Foster, VP of Fin. & Chief Accounting Officer
How do I buy shares of ImmunoGen?
Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of IMGN stock can currently be purchased for approximately $2.42.
How big of a company is ImmunoGen?
ImmunoGen has a market capitalization of $361.97 million and generates $53.82 million in revenue each year. The biotechnology company earns $-168,840,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 296 workers across the globe.View Additional Information About ImmunoGen.
What is ImmunoGen's official website?
How can I contact ImmunoGen?
ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
